ADMA 📈 ADMA Biologics - Overview

ADMA Biologics Inc. is a biopharmaceutical company that specializes in developing, manufacturing, and marketing plasma-derived biologics to treat immune deficiencies and infectious diseases globally.

The company's product portfolio includes BIVIGAM, an intravenous immune globulin (IVIG) used to treat primary humoral immunodeficiency (PI), a condition where the body's immune system is unable to produce sufficient antibodies to fight infections. Another IVIG product, ASCENIV, is also indicated for the treatment of PI.

In addition, ADMA Biologics offers Nabi-HB, a treatment for acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company is also developing a pipeline of plasma-derived therapeutics, including products focused on the treatment and prevention of S. pneumonia infection.

ADMA Biologics operates a network of source plasma collection facilities, which provide the raw material necessary for the production of its plasma-derived biologics. The company sells its products through a diverse distribution network, including independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.

Founded in 2004, ADMA Biologics is headquartered in Ramsey, New Jersey, and is committed to improving the lives of patients with immune deficiencies and infectious diseases. For more information, please visit their website at https://www.admabiologics.com.